Home > Insider Trading > Filing (0001103021-20-000028)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1103021	Biodelivery Sciences International Inc	BDSI	Pharmaceutical Preparations (2834)	352089858

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1739458	Herm Cukier	C/O Biodelivery Sciences Intl, Inc. 4131 Parklake Ave. Suite 225 Raleigh NC 27612	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-01-31	31,250	$0.00	67,631	No	4	M	Direct
Common Stock	Disposition	2020-02-03	31,850	$5.16	35,781	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2020-01-31	31,250	$0.00	31,250	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
62,500		2022-01-31	No	4	M	Direct

Footnotes

The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest equally on January 31, 2021 and January 31, 2022.
The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan, 11,850 of which were sold to cover the Reporting Person's tax liability upon the vesting of the RSUs.
On February 3, 2019, the Reporting Person sold an aggregate of 31,850 shares of the Issuer's Common Stock at a weighted average price of $5.16 per share. The highest sale price for the Common Stock was $5.24 per share and the lowest sale price was $5.10 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.